Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Net Margin (2020 - 2025)

Historic Net Margin for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to 13181.13%.

  • Silence Therapeutics' Net Margin fell 105653600.0% to 13181.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 249.86%, marking a year-over-year increase of 1580600.0%. This contributed to the annual value of 104.74% for FY2024, which is 649700.0% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Net Margin is 13181.13%, which was down 105653600.0% from 12211.61% recorded in Q2 2025.
  • Silence Therapeutics' 5-year Net Margin high stood at 48.61% for Q4 2024, and its period low was 313931.3% during Q1 2021.
  • Its 5-year average for Net Margin is 19369.82%, with a median of 368.38% in 2022.
  • As far as peak fluctuations go, Silence Therapeutics' Net Margin surged by 2000000000bps in 2021, and later crashed by -200643600bps in 2025.
  • Over the past 5 years, Silence Therapeutics' Net Margin (Quarter) stood at 328.85% in 2021, then increased by 4bps to 315.84% in 2022, then tumbled by -126bps to 713.01% in 2023, then skyrocketed by 107bps to 48.61% in 2024, then crashed by -27213bps to 13181.13% in 2025.
  • Its last three reported values are 13181.13% in Q3 2025, 12211.61% for Q2 2025, and 20091.55% during Q1 2025.